GlassScriptPhysician profile
Annabelle O Rivera
NPI 1871250191
$3,203.32
in general payments reported to CMS, 2019-2025
29 companies · $849 in 2025
The $849 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $335 · 2023: $1,151 · 2024: $869 · 2025: $849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,869.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,868.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $453.48 | 2022-2025 | |
| Novo Nordisk INC | $417.51 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Sk Life Science, INC. | $235.41 | 2022-2024 | |
| Ucb, INC. | $224.70 | 2022-2024 | Nayzilam, Briviact, Fintepla |
| Novartis Pharmaceuticals Corporation | $219.55 | 2023-2024 | |
| Pfizer INC. | $200.39 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $155.55 | 2023-2025 | Austedo Xr, Ajovy |
| Astrazeneca Pharmaceuticals LP | $136.45 | 2024-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $125.94 | 2023-2025 | Zepbound, Reyvow, Emgality |
| Gilead Sciences, INC. | $122.19 | 2023 | Epclusa |
| Otsuka America Pharmaceutical, INC. | $106.24 | 2023-2025 | Nuedexta, Rexulti |
| Averitas Pharma INC. | $103.83 | 2023 | Qutenza |
| Genentech USA, INC. | $89.08 | 2022-2024 | Ocrevus, Enspryng |
| Amneal Pharmaceuticals LLC | $83.08 | 2023-2024 | Rytary |
| Alnylam Pharmaceuticals INC. | $82.42 | 2023-2024 | Onpattro |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $69.65 | 2022-2024 | Vumerity, Tysabri |
| Emd Serono, INC. | $50.80 | 2022-2023 | Mavenclad |
| Argenx US, INC. | $48.32 | 2023 | Vyvgart |
| Biohaven Pharmaceutical Holding Company LTD. | $41.26 | 2022 | |
| Amgen INC. | $40.73 | 2024 | Uplizna |
| Upsher-Smith Laboratories LLC | $38.15 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.27 | 2025 | Trintellix |
| Csl Behring | $24.16 | 2023 | Hizentra |
| Ibsa Pharma INC. | $24.07 | 2025 | Licart, Flector, Tirosint |
| Abbott Laboratories | $21.06 | 2025 | Freestyle Libre |
| Axsome Therapeutics, INC. | $18.44 | 2024 | Sunosi |
| Grifols USA, LLC | $18.22 | 2024 | Gamunex-C |
| Kyowa Kirin, INC. | $13.87 | 2024 | Nourianz |
| Harmony Biosciences LLC | $13.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annabelle Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.